Correction
20 Oct 2022: The PLOS ONE Editors (2022) Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLOS ONE 17(10): e0276650. https://doi.org/10.1371/journal.pone.0276650 View correction
Notice of republication
This article was republished on October 20, 2020, to remove a Supporting Information file. Please download this article again to view the correct version.
Reference
- 1. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, et al. (2013) Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE 8(3): e54014. https://doi.org/10.1371/journal.pone.0054014 pmid:23516391
Citation: Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, et al. (2021) Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE 16(12): e0261994. https://doi.org/10.1371/journal.pone.0261994
Published: December 23, 2021
Copyright: © 2021 Shah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.